已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).

医学 达拉图穆马 内科学 耐火材料(行星科学) 肿瘤科 多发性骨髓瘤 胃肠病学 硼替佐米 物理 天体生物学
作者
María‐Victoria Mateos,Luděk Pour,Enrique M. Ocio,Pieter Sonneveld,Catarina Jansson Blixt,Kajsa Larsson,Linda Palmér,Paul Gerard Guy Richardson
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): TPS8051-TPS8051 被引量:3
标识
DOI:10.1200/jco.2021.39.15_suppl.tps8051
摘要

TPS8051 Background: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen + dex showed clinical efficacy and was well tolerated in pts with heavily pretreated RRMM (HORIZON; Richardson et al. J Clin Oncol. 2020 Dec 9 [Epub]). The ongoing phase 1/2 ANCHOR study (OP-104) established the optimal dose for melflufen + dex and dara, showing meaningful clinical activity and manageable safety at both melflufen doses tested in pts with RRMM (Ocio et al. ASH 2020. Oral 417). The aim of this study (OP-108; NCT04649060) is to evaluate the efficacy and safety of melflufen + dex and dara vs dara in pts with RRMM previously treated with an IMiD and a proteasome inhibitor (PI), similar to the indication for dara monotherapy. Methods: Pt enrollment has begun (N = 240 planned). Pts must be ≥ 18 y, double refractory to (or intolerant of) an IMiD and a PI or had ≥ 3 prior lines of therapy (LoTs) including an IMiD and a PI, have measurable disease, and Eastern Cooperative Oncology Group performance status ≤ 2. Pts with primary refractory disease and refractoriness to an anti-CD38 antibody are excluded. Pts will be randomized 1:1 to open-label melflufen + dex and dara (Arm A) or single-agent dara (Arm B) until progressive disease [PD] or unacceptable toxicity, stratified by prior LoT number. Pts in Arm B with PD can opt to receive Arm A triplet therapy. Arm A: melflufen 30 mg intravenously on d 1 of each 28-d cycle; dex 40 mg/wk orally (20 mg if aged ≥ 75 y); dara 1800 mg subcutaneously on d 1, 8, 15, and 22 of cycle 1 and 2, d 1 and 15 of cycles 3-6, and d 1 of cycles 7+. Arm B: dara at the same dosage as Arm A. Primary objective: superiority ( P value from the 2-sided statistical test < 0.05; upper limit of the 2-sided 95% CI for the hazard ratio < 1) of progression-free survival (PFS) in pts treated with triplet therapy vs dara. An estimated sample of 240 pts with 160 expected events (PD or death) and 15% assumed dropout rate would provide 90% power at a 2-sided log rank test at 5% significance level to detect a hazard ratio for death of 0.6. Key secondary endpoints: overall response rate (ORR; ≥ partial response [PR]), duration of response, and safety. Response will be assessed by a blinded independent review committee based on International Myeloma Working Group criteria. Other secondary endpoints: clinical benefit rate (≥ minimal response), time to response, time to progression, time to next treatment, and overall survival. Exploratory endpoints include: minimal residual disease in pts achieving ≥ very good PR, PFS following next line of treatment (PFS-2), pt-reported outcomes, pharmacokinetics, translational biomarkers, response rate in pts with extramedullary disease, and efficacy (including ORR) in Arm B pts who receive Arm A triplet therapy after PD. Clinical trial information: NCT04649060.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pik完成签到,获得积分20
1秒前
五岳三鸟完成签到,获得积分10
1秒前
摇摇晃晃完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
4秒前
SciGPT的应助被手提袋子的猫采纳,获得10
4秒前
5秒前
长情的寇完成签到 ,获得积分10
5秒前
77完成签到,获得积分10
5秒前
5秒前
6秒前
木华发布了新的文献求助10
7秒前
7秒前
胡图图完成签到 ,获得积分20
7秒前
酷波er的应助被无情妙菡采纳,获得10
8秒前
8秒前
科研通AI6.3的应助被积极北上采纳,获得10
8秒前
时老完成签到 ,获得积分10
9秒前
9秒前
Parker发布了新的文献求助10
11秒前
11秒前
hmv发布了新的文献求助10
12秒前
Arvin发布了新的文献求助10
12秒前
ar发布了新的文献求助10
13秒前
魏魏完成签到,获得积分10
13秒前
13秒前
zhzhzh发布了新的文献求助10
14秒前
Owen的应助被杨家南采纳,获得10
15秒前
15秒前
不吃鸭梨完成签到,获得积分10
17秒前
砍柴少年发布了新的文献求助10
17秒前
无限的含羞草完成签到,获得积分10
18秒前
19秒前
清风携来春夏完成签到,获得积分10
20秒前
Ava的应助被谦让的语儿采纳,获得10
20秒前
OK的应助被林夕采纳,获得80
20秒前
砰砰里完成签到,获得积分10
21秒前
阿狸完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643